Drug Profile

4D 310

Alternative Names: 4D-310

Latest Information Update: 18 Feb 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator 4D Molecular Therapeutics
Class Gene therapies
Mechanism of Action Alpha-galactosidase replacements; Gene transference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I/II Fabry's disease

Most Recent Events

12 Feb 2024 Interim pharmacodynamics, efficacy, and adverse events data from the phase I/II INGLAXA trial in Fabry's disease released by 4D Molecular Therapeutics
08 Jan 2024 4D Molecular Therapeutics anticipates FDA submission of data from the non-human primate (NHP) study of 4D-310 with the rituximab/sirolimus in Q2 2024
30 Oct 2023 4DMT expects to submit the phase I/II trial results to the FDA in Q2 2024

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com